fda declaratory order semaglutide shortage resolved february 21 2025 ends as sets deadline for compounders FDA Announces Resolution of Semaglutide

However, evidence suggests they may reduce migraines or lower the risk of heart disease in genetically susceptible people

Here is the escalation protocol

We will get definitive data on long-term weight loss sustainability, detailed body composition analysis, cardiovascular outcomes, liver fat effects at scale, and safety across diverse populations

However, while it may have an indirect effect on GLP-1 secretion, the studies are limited, and no large-scale clinical trials have confirmed its impact on weight loss through GLP-1 pathways alone

Changes relative to baseline lean mass were similar between the groups, and meta-regression analysis indicated that reductions in total body weight were significantly associated with fat mass loss but not with lean mass